1
|
Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon K, Patel K, Chung KM, Hermann A, Ullman E, Cruz J, Rafique A, Huang T, Fairhurst J, Libertiny C, Malbec M, Lee WY, Welsh R, Farr G, Pennington S, Deshpande D, Cheng J, Watty A, Bouffard P, Babb R, Levenkova N, Chen C, Zhang B, Romero Hernandez A, Saotome K, Zhou Y, Franklin M, Sivapalasingam S, Lye DC, Weston S, Logue J, Haupt R, Frieman M, Chen G, Olson W, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous CA. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 2020; 369:1010-1014. [PMID: 32540901 PMCID: PMC7299284 DOI: 10.1126/science.abd0827] [Citation(s) in RCA: 917] [Impact Index Per Article: 229.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Accepted: 06/11/2020] [Indexed: 12/18/2022]
Abstract
There is an urgent focus on antibodies that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike and prevent the virus from entering host cells. Hansen et al. generated a large panel of antibodies against the spike protein from humanized mice and recovered patients. From this panel, they identified several neutralizing antibodies, including pairs that do not compete for binding to the receptor binding domain. Baum et al. focused in on four of these antibodies. All four are effective against known spike variants. However, by growing a pseudovirus that expresses the spike in the presence of individual antibodies, the authors were able to select for spike mutants resistant to that antibody. In contrast, escape mutants are not selected when pseudovirus is grown in the presence of pairs of antibodies that either do not compete or only partially compete for binding to the RBD. Such a pair might be used in a therapeutic antibody cocktail. Science, this issue p. 1010, p. 1014 Neutralizing antibodies have become an important tool in treating infectious diseases. Recently, two separate approaches yielded successful antibody treatments for Ebola—one from genetically humanized mice and the other from a human survivor. Here, we describe parallel efforts using both humanized mice and convalescent patients to generate antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, which yielded a large collection of fully human antibodies that were characterized for binding, neutralization, and three-dimensional structure. On the basis of these criteria, we selected pairs of highly potent individual antibodies that simultaneously bind the receptor binding domain of the spike protein, thereby providing ideal partners for a therapeutic antibody cocktail that aims to decrease the potential for virus escape mutants that might arise in response to selective pressure from a single-antibody treatment.
Collapse
Affiliation(s)
- Johanna Hansen
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | - Alina Baum
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | | | - Vincenzo Russo
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | | | - Elzbieta Wloga
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | | | - Ying Yan
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | - Katrina Koon
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | - Krunal Patel
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | | | - Aynur Hermann
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | - Erica Ullman
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | - Jonathan Cruz
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | | | - Tammy Huang
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | | | | | - Marine Malbec
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | - Wen-Yi Lee
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | - Richard Welsh
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | - Glen Farr
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | | | | | - Jemmie Cheng
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | - Anke Watty
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | | | - Robert Babb
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | | | - Calvin Chen
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | - Bojie Zhang
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | | | - Kei Saotome
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | - Yi Zhou
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | | | | | - David Chien Lye
- National Centre for Infectious Diseases, Tan Tock Seng Hospital, Yong Loo Lin School of Medicine, Lee Kong Chian School of Medicine, 16 Jalan Tan Tock Seng, Singapore 308442, Singapore
| | - Stuart Weston
- Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - James Logue
- Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Robert Haupt
- Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Matthew Frieman
- Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Gang Chen
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | - William Olson
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | | | - Neil Stahl
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA
| | | | | |
Collapse
|